Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

Date 04 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Mutant-specific kinase inhibitors
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Presenter Jean-Charles Soria